Results 161 to 170 of about 65,633 (254)

Combined dorsal and ventral rhizotomy in non‐ambulatory individuals with mixed spastic bilateral cerebral palsy: A prospective registry analysis

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
This is the largest North American study of combined dorsal/ventral rhizotomy in non‐ambulatory, bilateral, mixed spastic–dyskinetic cerebral palsy (33 patients). Combined rhizotomy was safe, improved dystonia (Barry–Albright Dystonia Scale), spasticity (modified Ashworth scale), quality of life (Caregiver Priorities and Child Health Index of Life with
Adam C. Glaser   +6 more
wiley   +1 more source

Physical therapy interventions for children and adolescents with myelomeningocele: A systematic review

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Aim To systematically review the current evidence on physical therapy interventions for children and adolescents with myelomeningocele, the most complex and common presentation of spina bifida, to explore intervention components and the outcomes according to International Classification of Functioning, Disability and Health (ICF) domains, and ...
Lorena Costa Ferreira   +3 more
wiley   +1 more source

International consensus recommendations for identifying malnutrition in children with neurological impairment

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Children with neurological impairment (CNI) are at increased risk of malnutrition because of functional, medical, and socioeconomic challenges. However, difficulties in obtaining reliable anthropometric measurements and differences in body composition limit the usefulness of conventional nutritional indicators.
Sarah Vermilyea   +19 more
wiley   +1 more source

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek   +3 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy